Detailed information for compound 315097

Basic information

Technical information
  • TDR Targets ID: 315097
  • Name: (4-methoxyphenyl)-[2-[2-[(2R)-2-methylpyrroli din-1-yl]ethyl]-1-benzofuran-5-yl]methanone
  • MW: 363.45 | Formula: C23H25NO3
  • H donors: 0 H acceptors: 1 LogP: 4.89 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1ccc(cc1)C(=O)c1ccc2c(c1)cc(o2)CCN1CCC[C@H]1C
  • InChi: 1S/C23H25NO3/c1-16-4-3-12-24(16)13-11-21-15-19-14-18(7-10-22(19)27-21)23(25)17-5-8-20(26-2)9-6-17/h5-10,14-16H,3-4,11-13H2,1-2H3/t16-/m1/s1
  • InChiKey: ZGSUVVWUSJSBAJ-MRXNPFEDSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (4-methoxyphenyl)-[2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]benzofuran-5-yl]methanone
  • (4-methoxyphenyl)-[2-[2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl]-5-benzofuranyl]methanone
  • (4-methoxyphenyl)-[2-[2-[(2R)-2-methylpyrrolidino]ethyl]benzofuran-5-yl]methanone

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens histamine receptor H3 Starlite/ChEMBL References
Rattus norvegicus Histamine H3 receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus biogenic amine 5HT receptor Histamine H3 receptor   445 aa 405 aa 25.2 %
Loa Loa (eye worm) hypothetical protein Histamine H3 receptor   445 aa 384 aa 22.4 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trichomonas vaginalis dihydroorotate dehydrogenase, putative 0.0389 0 0.5
Trichomonas vaginalis dihydroorotate dehydrogenase, putative 0.0389 0 0.5
Trypanosoma brucei dihydroorotate dehydrogenase (fumarate) 0.0997 1 0.5
Wolbachia endosymbiont of Brugia malayi dihydroorotate dehydrogenase 2 0.0997 1 0.5
Entamoeba histolytica dihydropyrimidine dehydrogenase, putative 0.0389 0 0.5
Trypanosoma cruzi dihydroorotate dehydrogenase, putative 0.0997 1 1
Schistosoma mansoni dihydroorotate dehydrogenase 0.0997 1 0.5
Trichomonas vaginalis dihydroorotate dehydrogenase, putative 0.0389 0 0.5
Echinococcus multilocularis dihydropyrimidine dehydrogenase (NADP+) 0.0389 0 0.5
Plasmodium falciparum dihydroorotate dehydrogenase 0.0997 1 0.5
Trichomonas vaginalis dihydroorotate dehydrogenase, putative 0.0389 0 0.5
Trypanosoma cruzi dihydroorotate dehydrogenase (fumarate), putative 0.0997 1 1
Echinococcus granulosus dihydropyrimidine dehydrogenase NADP 0.0389 0 0.5
Brugia malayi Dihydroorotate dehydrogenase, mitochondrial precursor, putative 0.0997 1 1
Trichomonas vaginalis dihydropyrimidine dehydrogenase, putative 0.0389 0 0.5
Echinococcus multilocularis dihydropyrimidine dehydrogenase (NADP+) 0.0389 0 0.5
Leishmania major dihydroorotate dehydrogenase 0.0997 1 0.5
Echinococcus granulosus dihydropyrimidine dehydrogenase NADP 0.0389 0 0.5
Toxoplasma gondii dihydroorotate dehydrogenase reveal, putative 0.0997 1 0.5
Trichomonas vaginalis dihydroorotate dehydrogenase, putative 0.0389 0 0.5
Plasmodium vivax dihydroorotate dehydrogenase, mitochondrial precursor, putative 0.0997 1 0.5
Mycobacterium leprae Probable dihydroorotate dehydrogenase PyrD 0.0997 1 0.5
Trypanosoma cruzi dihydroorotate dehydrogenase, putative 0.0997 1 1
Mycobacterium ulcerans dihydroorotate dehydrogenase 2 0.0997 1 0.5
Mycobacterium tuberculosis Probable dihydroorotate dehydrogenase PyrD 0.0997 1 0.5

Activities

Activity type Activity value Assay description Source Reference
CLb (ADMET) = 3.05 l hr-1 kg-1 Clearance of the compound was observed in rat after intravenous administration of 1-5 mg/kg ChEMBL. 15634000
Concentration (ADMET) = 848 ng g-1 Concentration of the compound in brain of rats after 1 hr of intravenous administration ChEMBL. 15634000
F (ADMET) = 20 % Oral bioavailability in rat (dose 1-5 mg/kg i.v.) ChEMBL. 15634000
Ki (binding) = -9.28 In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor ChEMBL. 15634000
Ki (binding) = -8.57 In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor ChEMBL. 15634000
Ki (binding) = 0.52 nM In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor ChEMBL. 15634000
Ki (binding) = 0.52 nM In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor ChEMBL. 15634000
Ki (binding) = 2.69 nM In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor ChEMBL. 15634000
Ki (binding) = 2.69 nM In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor ChEMBL. 15634000
Log Ki (binding) = 8.57 In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor ChEMBL. 15634000
Log Ki (binding) = 9.28 In vitro binding affinity was determined as displacement of [3H]-N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor ChEMBL. 15634000
pKb (functional) = 8.09 Tested for its ability to block human histamine H3 receptor activation by the agonist R-alpha-methyl histamine in a [Ca2+] flux assay ChEMBL. 15634000
pKb (functional) = 8.09 Tested for its ability to block human histamine H3 receptor activation by the agonist R-alpha-methyl histamine in a [Ca2+] flux assay ChEMBL. 15634000
T1/2 (ADMET) = 2.5 hr Half life of the compound was observed in rat after intravenous administration of 3-5 mg/kg; (n=3) ChEMBL. 15634000
Volume (ADMET) = 11.6 l hr-1 Volume of distribution of the compound was observed in rat after intravenous administration of 1-5 mg/kg ChEMBL. 15634000

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.